PT-141, also known as Bremelanotide, is a synthetic peptide and melanocortin receptor agonist. Unlike traditional ED medications that work on blood vessels, PT-141 works centrally — stimulating melanocortin receptors in the brain to trigger sexual arousal and desire. It has shown a clinical success rate of over 80% in trials and is used for both men and women experiencing sexual dysfunction.

PT-141 is administered as a subcutaneous injection — meaning it is injected just under the skin into fatty tissue, such as the abdomen or thigh. The standard dose is 10 units (1 mg) twice per week. Your provider will walk you through proper injection technique during your onboarding, and most patients find it straightforward after the first use.

PT-141 is typically administered 30 minutes to a few hours before anticipated sexual activity. Because it is injected subcutaneously and enters the bloodstream directly, onset is generally faster than oral medications. Individual response times may vary, and your provider may adjust timing recommendations based on your personal experience.

PT-141 has been shown to increase sexual desire, improve erectile function, and enhance overall sexual satisfaction. For women, it has been approved for treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal patients. For men, it offers an effective alternative when other ED treatments have failed, and may increase libido and arousal beyond what vascular-only treatments can provide.

The most notable long-term effect of PT-141 use is skin darkening (hyperpigmentation) over time, due to its activity at melanocortin receptors that also regulate pigmentation. Other reported side effects can include temporary nausea, flushing, or headache following injection. PT-141 should not be used by individuals with cardiovascular disease without physician clearance. Always disclose your full medical history to your provider before starting treatment.

Yes — because PT-141 stimulates melanocortin receptors, which are also involved in skin pigmentation, prolonged use can lead to gradual skin darkening (hyperpigmentation). This is a known and documented effect. Your provider will discuss this with you during consultation so you can make an informed decision about treatment.

Bremelanotide (PT-141) has been FDA-approved under the brand name Vyleesi for treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. The compounded form of PT-141 used at Testosteroneshots.com is prepared by licensed compounding pharmacies and requires a prescription from a licensed provider, but is not itself FDA-approved as a compounded product. As with all compounded medications, it has not been evaluated by the FDA for safety, efficacy, or quality in its compounded form.

Yes. PT-141 is a prescription medication and cannot be dispensed without a valid prescription from a licensed healthcare provider. At Testosteroneshots.com, our process includes a medical intake and provider evaluation — so if PT-141 is appropriate for you, your prescription is handled entirely online, with no clinic visits required.